PlaqueTec is paving the way to personalised medicine for Coronary Artery Disease (CAD).
We envision a future in which clinicians can accurately assess patients’ risk of future events and apply individualised treatment. Our Liquid Biopsy System™ (LBS™) is a revolutionary technology that facilitates the identification and collection of biomarker samples from vulnerable plaque within coronary arteries, providing clinically valuable information pertaining to vascular function, inflammation, and coronary plaque progression.
25 June 2018:
20 June 2018
30 May 2018
16 April 2018
NEWS & FEATURES
Guided by world leaders in cardiovascular medicine, PlaqueTec is mapping the biological processes of CAD in more detail than has ever been possible. We are building a database of identified biomarkers to be used by CAD clinicians, researchers, and biopharmaceutical companies to conduct translational research and develop next-generation personalised therapies.
Our aim is to provide better benchmarks for new and existing drug performance, and to facilitate the development of new drugs that target the inflammatory processes underlying CAD progression.
PlaqueTec is pioneering the development of biomarker-based strategies to transform the prevention, diagnosis, and treatment of Coronary Artery Disease, the leading cause of death worldwide.
Watch the PlaqueTec Liquid Biopsy System™ in action.